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a  b  s  t  r  a  c  t
The  orthogonal  heart-cutting  liquid  chromatography  (LC)  modes  coupled  to high-resolution  tandem  mass
spectrometry  (HRMS/MS)  provide  a number  of  possibilities  to  enhance  selectivity  and  sensitivity  for the
determination  of targeted  compounds  in  complex  biological  matricies.  Here  we  report  the development  of
a new  fast  2D-LC-(HRMS/MS)  method  and  its  successful  application  for  quantitative  determination  of  the
level  of  plasma  and  brain  N,N-dimethyltriptamine  (DMT)  using  -methyltryptamine  (AMT)  as  internal
standard  in  an  experimental  model  of cerebral  ischemia/reperfusion  using  DMT  administration.  The  2D-
LC separation  was  carried  out  by a combination  of  hydrophilic  interaction  liquid  chromatography  (HILIC)
in the  first  dimension  followed  by second-dimensional  reversed-phase  (RP)  chromatography  within  a
total run  time  of  10 min.  The  enrichment  of  HILIC  effluent  of interest  containing  DMT was  performed
using  a C18  trapping  column.  During  method  development  several  parameters  of  sample  preparation
procedures,  chromatographic  separation  and  mass  spectrometric  detection  were  optimised  to achieve
high DMT  recovery  (plasma:  90  %,  brain:  88  %)  and  sensitivity  (plasma:  0.108  ng/mL  of LOD,  brain:  0.212
ng/g  of  LOD)  applying  targeted  analytical  method  with  strict  LC and  HRMSMS  confirmatory  criteria.Concerning  rat  plasma  sample,  the  concentration  of  DMT  before  hypoxia  (49.3–114.3  ng/mL  plasma)
was  generally  higher  than  that after hypoxia  (10.6–96.1  ng/mL  plasma).  After  treatment,  the concentra-
tion  of  DMT  in brain  was  elevated  up to the range  of  2–6.1 ng/g.
Overall,  our  analytical  approach  is suitable  to detect  and  confirm  the  presence  of  DMT  administered  to
experimental  animals  with  therapeutic  purpose  in a reliable  manner.
©  2020  Elsevier  B.V.  All  rights  reserved.. Introduction
DMT  is an endogenous hallucinogen and trace amine found
n various tissues such as the brain, pineal gland and lung, and
ody fluids such as urine, cerebrospinal fluid and blood plasma in
ammals [1–4]. DMT  is produced by somatic cells under physi-
logical conditions [1,3], and its concentration has been found to
ncrease in response to pathophysiological homeostatic challenges
e.g. hypoxia or oxidative stress) [1,3]. Concurrently, DMT  is best
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731-7085/© 2020 Elsevier B.V. All rights reserved.known as an indole alkaloid typically synthesised by plants like
Psychotria viridis and Diplopterys cabrerana [5].
Although DMT  was  traced with gas-chromatography in body
fluids of psychiatric patients and control subjects [3,4], its physi-
ological role is still to be understood, in particular, because DMT
undergoes rapid enzymatic degradation by monoamine oxidases
(MAO) [3]. On the other hand, DMT  has been implicated in neuro-
protection at high concentration, either synthesised in the nervous
tissue in response to hypoxia or oxidative stress, or originating from
the lung and reaching the brain via the blood stream [1,6]. The
putative neuroprotective action of DMT  has been utilised in exper-
imental models of cerebral or renal ischemia. DMT administered at
supraphysiological concentration to experimental rodents resulted































































sham-operated (n = 3). All rats were fixed by their head in a prone T. Körmöczi, Í. Szabó, E. Farkas et al. / Journal of Pha
ell culture of human cerebrocortical neurons exposed to hypoxia
8].
Early researches of DMT  focused primarily on the psychological
nd pharmacological effects of consuming ayahuasca [5]. During
he last 60 years, many studies reported finding DMT  and its
etabolites in animal tissue and human urine, blood and cere-
rospinal fluid using liquid chromatography (LC). Nowadays liquid
hromatography–tandem mass spectrometry (LC–MS/MS) is one
f the most widely used bioanalytical methods for quantification of
mall molecules in biological samples. It is due to its high sensitivity
nd high selectivity, thus being able to provide more reliable data
han the LC technique itself, which is also true of the analysis of DMT
9], only a few studies reported the presence of DMT  in mammalian
issue; for instance, in pineal gland microdialysate of rat [2], rat kid-
ey, lung, liver, brain, human lung and rabbit liver [10]. According
o certain viewpoints, detection of endogenous DMT  is not rele-
ant when it is exogenously administered due to the dissimilar
oncentration range [11].
The ultimate purpose of our upcoming study is to evaluate
he neuroprotective action of DMT  in an experimental model of
erebral ischemia/reperfusion, aggravated by transient anoxia and
ecurrent spreading depolarisations. Here, we set out to establish
 novel, highly sensitive analytical tool to determine the concen-
ration of endogenous DMT  in our model and to measure the
ccumulation of intravenously administered exogenous DMT  in
lood plasma and brain tissue.
In modern pharmaceutical analysis, quantitation of analyte
r analytes of interest in complex biological matrices requires
igh selectivity and sensitivity. Nowadays, two-dimensional liq-
id chromatography (2D-LC) is one of the most powerful analytical
ools to improve the quality of obtained data, especially in com-
ination with HRMS/MS. The comprehensive and heart-cutting
nalyses are known to be the main techniques of 2D-LC. The heart-
utting mode is a targeted 2D technique, because only a selected
luent fraction (single heart-cutting) or fractions (multiple heart-
utting) are collected, trapped for second-dimensional separation
12–14].
Nowadays, the typical method utilised for determination of
dministered DMT  in plasma and brain sample is reversed phase
hromatographic separation coupled to tandem mass spectrome-
ry using electrospray or atmospheric pressure chemical ionization
n positive mode [15–18]. However, the high resolution accurate
RMS/MS method, in combination with orthogonal 2D-LC separa-
ion in comparison with one dimensional LC-HRMS/MS methods,
as the ability to provide more reliable data. Furthermore, it gives
he opportunity to use lower amounts of samples with similar or
etter limit of detection for DMT. The required amount of bio-
ogical sample is a critical issue, especially in pharmacokinetics
ssays or when the available sample is limited for instance at a
epeated sampling of blood from rat and mouse. Another key fac-
or of method development is run time, which should be kept as
ow as possible. For determination of DMT  in complex biological
amples such as brain and plasma, the application of the gradient
lution is essential, therefore the total run time of analysis increases
y the time of column wash and equilibration. In the literature, the
otal run time of gradient LC–MS/MS analysis of DMT  can be found
n the range of 11.5−25 min  in brain and plasma samples [15–18].
hus, the main goals of this study were the development of a fast
eart-cutting 2D-LC-HRMS/MS method and optimisation of sam-
le preparation procedures for the quantitative analysis of DMT in
at brain and plasma using a relatively low amount of biological
amples. The method thus developed was applied for the deter-
ination of DMT  level in rat plasma and brain of experimental
odel of cerebral ischemia/reperfusion using DMT  administra-
ion.utical and Biomedical Analysis 191 (2020) 113615
2. Materials and methods
2.1. Chemicals and standards
N,N-Dimethyltryptamine (DMT) standard with purity >98.5
% was  obtain from Lipomed AG (Arlesheim, Switzerland). -
Methyltryptamine (AMT) with purity >99 % was  kindly provided
by the Department of Forensic Medicine, Faculty of Medicine, Uni-
versity of Szeged, Hungary, and used as internal standard (IS).
Acetonitrile, ammonium formate, formic acid, methanol, water, (all
LC–MS grade), 35 % ammonia solution, ethyl acetate (HPLC grade)
and reagent grade perchloric acid (70 %) were purchased from
VWR  (Radnor, PA, USA). Isoflurane (Medicus Partner Ltd., Biator-
bágy, Hungary) for in vivo preparations, the anaesthetic isoflurane
was produced by CP-Pharma (Handelsgesellschaft mbH, Germany);
atropine and lidocaine were purchased from Egis Pharmaceuticals
Ltd. (Budapest, Hungary); EDTA and pargilin from Sigma-Aldrich,
(St Louis, MO,  USA); chloral hydrate from Molar Chemicals Ltd.
(Budapest, Hungary), and sterile physiological saline from B. Braun
AG, (Melsungen, Germany).
2.2. Animals and tissue samples
The experimental procedures were approved by the National
Food Chain Safety and Animal Health Directorate of Csongrád
County, Hungary (license No. XXXII./2015). The procedures were
performed according to the guidelines of the Scientific Committee
of Animal Experimentation of the Hungarian Academy of Sciences
(updated Law and Regulations on Animal Protection: 40/2013. (II.
14.) Gov. of Hungary), following the EU Directive 2010/63/EU on
the protection.
Young 3 months old, male Sprague-Dawley rats (Charles River
Laboratories, 328 ± 18 g) were used in this study. Standard rodent
chow and tap water were supplied ad libitum. The animals were
housed under constant temperature, humidity and lighting condi-
tions (23 ◦C, 12:12 h light/dark cycle, lights on at 7 a.m.).
We set out to determine the blood plasma and brain concentra-
tion of DMT  synthesised by tissues in response to ischemia/hypoxia
(i.e. endogenous DMT), and DMT  content of blood plasma and brain
tissue after DMT  administered to the animals by intravenous (i.v.)
infusion (i.e. exogenous DMT), with the ultimate purpose to achieve
neuroprotection against cerebral ischemia/hypoxia.
2.3. Surgical procedures and collection of samples
For endogenous DMT  measurements, rats were injected
intraperitoneally (i.p.) with pargilin (50 mg/bwkg, Sigma-Aldrich,
USA), an effective monoamine-oxidase (MAO) inhibitor, a day prior
to and on the day of the experiments. For the surgical procedures,
animals were anaesthetised with 1.5–2 % isoflurane in N2O:O2 (3:2)
and were allowed to breathe spontaneously through a head cone
during the experiment. Body temperature was  kept at 37.2 ◦C by
a feedback-controlled heating pad (Harvard Apparatus, Holliston,
MA,  USA). Atropine (0.1 %, 0.05 mL;  i.m.) was administered as pre-
medication in order to avoid the production of airway mucus. The
left femoral artery was  cannulated for blood sampling, and the
adjacent femoral vein was  cannulated for drug administration. For
the later initiation of incomplete global forebrain ischemia (n =
4), a midline incision was  made in the neck, and each common
carotid artery was  carefully looped around with a surgical thread.
Lidocaine (1 %) was used for local anaesthesia. Control rats wereposition in a stereotaxic apparatus.
After a baseline period (5–10 min), cerebral ischemia was



























































T. Körmöczi, Í. Szabó, E. Farkas et al. / Journal of Pha
n hour after ischemia onset, the insult was aggravated by hypoxia
chieved by the complete withdrawal (5 min, endogenous DMT
easurement) or controlled withdrawal (1 min, exogenous DMT
easurement) of O2 from the anaesthetic gas mixture. The com-
lete withdrawal of O2 terminated the experiments, while the
ontrolled withdrawal of O2 was followed by reoxygenation and the
rompt release of the carotid arteries to allow cerebral reperfusion
or another hour.
In rats prepared for the measurement of exogenous DMT, the
dministration of DMT  (1 mg/bwkg/h in physiological saline) or
ts vehicle (physiological saline) started upon ischemia induc-
ion through the femoral vein, with the aid of a microinjection
yringe pump (CMA/100 Micro Injection Pump, Carnegie Medicine,
tockholm, Sweden). The i.v. infusion of DMT  was continuous and
aintained until the end of the experiment.
For the determination of the endogenous DMT  content of blood
lasma and brain tissue, 5 mL  arterial blood was  collected imme-
iately after the 5-min withdrawal of O2. The full blood was
entrifuged promptly in an Eppendorf tube (5000 g, 5 min, 4 ◦C,
eraeus Fresco 17 Microcentrifuge, Thermo Scientific, Waltham,
A,  USA) coated with EDTA (ethylenediaminetetraacetic acid), and
upernatant plasma (1 mL)  was separated into another Eppendorf
ube. The brains were removed and then, after snap-frozen in liq-
id nitrogen, were stored together with the plasma at −80 ◦C until
urther processing.
For the measurement of blood plasma and brain tissue concen-
ration of exogenous DMT, blood samples were collected through
he femoral artery at baseline (i.e. prior to ischemia onset), under
schemia, after hypoxia and under reperfusion. The animals were
ranscardially perfused with ice-cold physiological saline under
eep chloral hydrate anaesthesia (5 %, i.p., 500 mg/bwkg) at the
nd of the experimental protocol to eliminate any blood from the
rain. The brains were removed and snap frozen in liquid nitrogen,
hen stored at −80 ◦C until further processing. Blood samples were
rocessed as described above and yielded 0.2 mL  plasma.
.4. Sample preparation of rat plasma samples
Prior to extraction of plasma, 5 L IS (200 ng/mL in methanol)
nd 5 L methanol was added to 50 L of plasma sample. After vor-
ex, 50 L of 5.3 v/v% ammonia solution and 300 L ethyl acetate
ere added followed by 30 s vortex and shaking for 10 min at room
emperature (250 rpm, orbital, Dual-Action Shaker KL 2, Edmund
ühler, Bodelshausen, Germany). Then the mixture was rested for
 min  on ice. The sample was centrifuged at 4 ◦C for 12 min  at
1,000 g (Universal 320 R, Hettich, Tuttlingen, Germany). 250 L
f the upper phase was collected and the lower phase was re-
xtracted with 300 L of ethyl acetate. After centrifugation, 300 L
f the upper phase was combined with the first portion of aliquot
nd was dried under nitrogen at room temperature. For 2D-LC-
RMS/MS measurements, the dried extracts were dissolved in 100
L methanol.
.5. Sample preparation of rat brain samples
Rat brain tissue was homogenized based on the work by
ärkkäinen [10]. The weighed brain sample (1 g tissue, 7 mL  ice-
old 0.1 M HClO4) was  added into 12 mL  tubes. The sample was
onicated on ice with Biologics Model 150 V T ultrasonic homog-
nizer (BioLogics, Inc., Manassas, VA, USA) for 3 × 1 min  using
edium power setting on the micro-tip probe and an 80 % pulse.
fter centrifugation at 9000g for 12 min  at 4 ◦C (Universal 320 R,
ettich, Tuttlingen, Germany), 5 L IS (200 ng/mL in methanol),
 L methanol and finally 200 L of 8 % ammonia solution were
dded to 400 L brain homogenate. After vortex, 500 L ethyl
cetate was added, followed by 30 s vortex and shaking for 10 minutical and Biomedical Analysis 191 (2020) 113615 3
at room temperature (250 RPM, orbital, Dual-Action Shaker KL 2,
Edmund Bühler, Bodelshausen, Germany). Then the mixture was
rested for 5 min  on ice. The sample was  centrifuged at 4 ◦C for
12 min  at 21,000g (Universal 320 R, Hettich, Tuttlingen, Germany).
350 L of the upper phase was  collected and the lower phase was
re-extracted with 500 L of ethyl acetate. After centrifugation, 500
L of the upper phase was combined with the first portion of the
aliquot followed by drying under nitrogen at room temperature.
For the 2D-LC-HRMS/MS measurements, the dried extracts were
dissolved in 100 L methanol.
2.6. Preparation of samples for calibration and validation
1.00 mg/mL  stock solutions of DMT  and AMT  were prepared
by dissolving approximately 1 mg aliquots of each component
in methanol. The stocks were used for the preparation of work-
ing calibration standards. Eight DMT  working calibration standard
solutions were prepared in methanol. For external calibration, the
sample preparation was  similar to that of the treated samples,
except that the sample was spiked with 5 L of the given concen-
tration of DMT  instead of 5 L methanol. Thus, the final volumes
were the same in the calibration samples and the treated samples.
External calibration curves using internal standard were used with
the following calibration points of DMT  (0, 0.2, 2, 10, 20, 40, 100
and 200 ng/mL plasma) in plasma and (0, 0.175, 1.75, 8.75, 17.5, 35,
87.5, 175 and 350 ng/g) in brain. Each calibration point was injected
in replicate and repeatability was evaluated for the retention times
of DMT.
The limit of detection (LOD) and limit of quantification (LOQ)
were calculated, respectively, on the basis on the standard devia-
tion (SD) and the slope (S) of the calibration curve.
LOD = 3.3 × SD
S
LOQ = 10 × SD
S
Accuracy and precision was  determined by analysing samples
at “Low” (10 ng/mL in plasma and 17.5 ng/g in brain), “Mid” (40
ng/mL in plasma and 35 ng/g in brain) and “High” (200 ng/mL in
plasma and 350 ng/g in brain) concentrations in three analytical
runs.
Carry over was assessed by injecting a blank sample after inject-
ing a high concentration of analyte (plasma: 200 ng/mL, brain: 350
ng/g).
To evaluate the stability of DMT  in plasma and brain samples in
the autosampler (16 ◦C), calibration solutions (20 ng/mL in plasma
and 35 ng/g in brain) were re-injected 24 h after the first injec-
tion and compared to the original concentrations. The results of the
second runs were expressed as the percentage of their respective
values in the first run.
2.7. 2D-LC-HRMS/MS conditions
The 2D-LC-HRMS/MS analysis was performed with Thermo
Scientific Q Exactive Plus hybrid quadrupole-Orbitrap (Thermo
Fisher Scientific, Waltham, MA,  USA) mass spectrometer coupled
to a Waters Acquity I-Class UPLCTM (Waters, Manchester, UK)
apparatus. The UHPLC system equipped with two  binary solvent
managers, an auto-sampler and a column manager with two  six-
port, two-position automatic switch valves. The eluent of the trap
column was diluted using a Knauer HPLC-pump 64 (Knauer, Berlin,
Germany) and a high-pressure stainless steel tee (IDEX, Oak Harbor,
WA,  USA). The first- and second-dimensional analytical columns






























































those over other C18 columns. Finally, an Omega C18 microbore
column with a particle size of 1.6 m was selected for further opti- T. Körmöczi, Í. Szabó, E. Farkas et al. / Journal of Pha
hile the trap column was inserted into an l-7350 LaChrom column
ven (Merck, Darmstadt, Germany).
In the final 2D-LC-HRMS/MS analysis, the first-dimensional
hromatographic separation was carried out on a Kinetex HILIC
olumn (150 × 2.1 mm,  2.6 m,  100 Å, Phenomenex) protected
y a HILIC guard column (4 × 3 mm,  2.6 m,  100 Å, Phenomenex),
hile the second-dimensional separation was performed on a Luna
mega Polar C18 column (50 × 2.1 mm,  1.6 m, 100 Å, Phe-
omenex). For the enrichment of the analytes, a Luna C18 trap
olumn (20 × 2 mm,  5 m,  100 Å, Phenomenex) was applied and
onnected through two six-port valves (Fig. 1).
During method development, the following chromatographic
olumns were tested in the first dimension: Luna HILIC (150 ×
 mm,  3 m,  200 Å, Phenomenex), Luna Omega Sugar (100 ×
.1 mm,  3 m,  100 Å, Phenomenex), Luna NH2 (150 × 2 mm,
 m,  100 Å, Phenomenex) and Kinetex C18 (50 × 2.1 mm,  2.6
m, 100 Å, Phenomenex). Columns tried in the second dimension
ere Luna Omega PS C18 (50 × 2.1 mm,  1.6 m,  100 Å, Phe-
omenex), Acquity UPLC BEH C18 (50 × 2.1 mm,  1.7 m,  130 Å,
aters) and CORTECS UPLC C18+ (50 × 2.1 mm,  1.6 m,  90 Å,
aters). By the scheduled switching of the six-port valves, the
ilute mobile phase from the HILIC column in first dimension was
rapped on Luna C18 enrichment column (Fig. 1). For the preven-
ion of the elution of targeted compounds from the enrichment
olumns during the trapping process, the diluter pump delivered
queous ammonia solution (pH 10.2) at 3 mL/min flow rate into
he static mixing tee, which was connected to a HILIC column and
 six-port valve. The temperature of trap columns was  maintained
t 50 ◦C (Fig. 1).
In the first dimension, a 10 L sample was injected with the
artial Loop With Needle Overfill injection mode on a Kinetex
ILIC column using the programmed gradient of eluent A (50 mM
mmonium formate solution) and eluent B (0.1 % formic acid in
cetonitrile). The column temperature was set at 50 ◦C during the
nalysis. In the second dimension, eluent A and B, respectively,
ere 0.1 % formic acid solution and 0.1 % formic acid in acetoni-
rile. The mobile phase washed the substances trapped on a Luna
18 enrichment column onto a Luna Omega Polar C18 column. The
econd-dimensional column was maintained at 50 ◦C. The gradient
rograms of both dimensional separations with the two six-port
alve positions are detailed in Table 1.
The mass spectrometer was operated in positive-ion mode
sing a heated electrospray ionisation (ESI) source with the fol-
owing conditions: capillary temperature 250 ◦C, S-Lens RF level
0, spray voltage 3.5 kV, sheath gas flow 45, sweep gas flow 2 and
uxiliary gas flow 10 in arbitrary unit. In parallel reaction mon-
toring (PRM) with resolution of 17,500 (FWHM), the automatic
ain control (AGC) setting was defined as 1 × 106 charges and
he maximum injection time was set to 50 ms  The width of the
solation window of precursor ion was 2 Da. Collision energies
CE) were optimised for respective transitions of DMT  and AMT
Fig. 2). The additional main HRMS/MS parameters are summarized
n Table 2.
During 2D-LC-HRMS/MS measurements, the eluate was passed
nto the ESI source only in the time range of 4.5–5.5 min  in order
o decrease the contamination of the MS.  For the remaining time,
he ESI source was rinsed with acetonitrile/water solution (90/10,
/v) at a flow rate of 0.1 mL/min by an auxiliary pump (Knauer
PLC-pump 64, Knauer, Berlin, Germany).
The LC system was controlled by MassLynx 4.1 SCN 901 (Waters,
ilford, MA,  USA). The control of the MS  system and MS  data acqui-
ition was conducted by XcaliburTM 4.1 software (Thermo Fisher
cientific, Waltham, MA). GraphPad Prism 5 statistical software
GraphPad Software, San Diego, CA, USA) was used for drawing col-
mn  diagrams, boxplots and point graphs, and the calculation of
aired t-test.utical and Biomedical Analysis 191 (2020) 113615
3. Results and discussion
3.1. Development of heart-cutting 2D-LC-HRMS/MS
During analytical method development several parameters
were tested in both dimensions and trapping procedure such as
mobile phase composition, column temperature, gradient steep-
ness, flow rate, type and length of column. For ESI-HRMS/MS
detection of DMT  and AMT, the appropriate transitions (quantifiers,
qualifiers ions) were selected and the related collision energies and
ESI parameters were optimised (Fig. 2).
The main aim of optimisation of HILIC separation of DMT  and
AMT  (internal standard) was  to achieve proper retain and peak
shape of DMT  and AMT, which is feasible involving equilibration
time within maximum 10 min  as a planned complete runtime of
online 2D measurements. For the optimisation of HILIC, narrow-
bore columns (3 and 2.1 mm)  with length of 100 mm and 150 mm,
packed with totally porous or core-shell particles were compared
with different solid phases. The presence of water at a minimum
quantity of 3 % in the initial mobile phase composition is essential
in HILIC. By varying its concentration, the retention mechanism and
separation can be influenced in both isocratic and gradient elutions
[19].
The MS-compatible ammonium formate as mobile phase mod-
ifier was selected at 50 mM concentration applying acetonitrile as
the organic content of the mobile phase. The flow rate is also a crit-
ical parameter in the first dimension, since it must be kept as low
as possible, thus assisting the trapping of the investigated analytes.
Unfortunately, the undesired effect of low flow rate is peak broad-
ening. In our case, a flow rate of 0.3 mL/min provided an acceptable
compromise. For appropriate column selection, four HILIC columns
were tested (Luna HILIC, Kinetex HILIC, Luna Omega Sugar, Luna
NH2) using a 50 mM ammonium formate aqueous solution/0.1 %
formic acid in acetonitrile (90/10, v/v) mobile phase composition
for 6 min. A comparison of the separation performance of AMT  and
DMT  on the four HILIC columns revealed that application of Luna
Omega was  disadvantageous for both retention and peak shapes
of DMT  (1.35 min) and AMT  (1.40 min). Similarly, when Luna NH2
was used, AMT  gave an extreme peak broadening, whereas DMT
(1.23 min) had a relatively low retention. In the case of Luna HILIC,
significantly higher retention times were found for both DMT (3.89
min) and AMT  (4.84 min) with a peak width of approximately 1
min. Interestingly, the elution order changed using Kinetex HILIC
column, and the retention times of both analytes were higher than
6 min. Therefore, the eluent strength was  increased to 50 mM
ammonium formate aqueous solution/0.1 % formic acid in acetoni-
trile (85/15, v/v) resulting in 3.09 min  and 2.72 min  retention time
for DMT  and AMT  and a peak width of approximately 0.5 min.
Consequently, this composition was selected in the final method.
Interestingly, the elution order changed using the Kintex HILIC col-
umn  in comparison with those of the other three columns.
In the case of optimisation of second dimension, the primary
aim was to obtain sharp, symmetric chromatographic peaks (high
sensitivity) with close retentions for both compounds using gra-
dient elution and keeping 10 min  total run time of 2D analysis.
Initially, five C18 columns were compared, using gradient elution
(0–1 min  10 % B, 1–4 min  40 % B, where eluents A and B, were 0.1
% formic acid aqueous solution and 0.1 % formic acid in MeOH),
respectively. Using CORTECS C18, Omega PS C18, and Kinetex C18,
relatively high peak widths (∼ 0.5 and 0.3 min  for DMT  and AMT)
were observed. The application of BEH C18 and Omega C18 pro-
vided higher retention times and lower peak widths compared withmisation procedures. The nature of organic solvent influenced both
peak width and retention. For DMT  and AMT, it could be concluded
T. Körmöczi, Í. Szabó, E. Farkas et al. / Journal of Pharmaceutical and Biomedical Analysis 191 (2020) 113615 5





ig. 2. The structure of DMT  (A) and AMT  (B) with assumed fragmentation cleavaghat ACN instead of MeOH gave lower retention, better peak shape
nd lower peak width. For obtaining proper retention within 10-
in  runtime including washing and re-equilibration of the column exact mass of quantifier and qualifier ions and their optimised collision energy.connected to trapping column in the second dimension, the tem-
perature of the column, the flow rate and the gradient steepness
were adjusted and synchronized with the HILIC method.
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Table 1
The gradient programs of first and second dimension with the two  six-port valve positions and analysis mode.
Gradient program of 1st dimension Gradient program of 2nd dimension Timetable of valves Mode
Time (min) B% Flow rate (mL/min) Time (min) B% Flow rate (mL/min) Time (min) Valve 1 Valve 2
0.00 85 0.3 0.00 2 0.5 0.00 Position 2 Position 2
1.80 Position 1 Position 1
trapping
3.00  2 0.5
3.10 2 0.3
3.50 2 0.3 3.50 Position 2 Position 2







8.00 Position 1 Position 1
8.01 Position 2 Position 2
9.00  100 0.5
9.50 2 0.5 9.50 Position 1 Position 1
9.51 Position 2 Position 2
9.90  85 1.2
10.00 85 0.3 10.00 2 0.5
Table 2
Main HRMS/MS parameters for DMT  and AMT  (internal standard) and retention times.
Analyte Chemical
formula










 144.0808 21 4.99




































Fig. 3. The effect of the flow rate of diluting eluent to trapping efficiency of DMTDMT  C12H16N2 189.1386 58.0651 10
AMT  C11H14N2 175.1230 158.0964 10
The online trapping of DMT  and AMT  from the eluate of the
rst-dimensional HILIC column in a 2D-LC system was performed
y using C18 trap column. This highly orthogonal separation (HILIC
 RP-LC) required to decrease the solvent strength of the effluent of
he first-dimensional column in order to retain both analytes on the
nrichment column. Fig. 1. demonstrates the experimental config-
ration of our 2D-LC-HRMS/MS system. The 2D interface between
ILIC and RP columns consists of C18 trap column and two auto-
atically operated two-position six-port valves. The dilution of the
rst-dimensional HILIC eluate was performed by applying a diluter
ump connected to the column through a static mixing tee (Fig. 1).
he selection of an appropriate diluter solvent and flow rate was
rucial to enrich DMT  and AMT  on the trapping column with high
fficiency. It can be explained by the high eluting power of eluate
f HILIC separation in RP mode and, consequently, it needed to be
iluted with a weak RP solvent. Initially, 0.1 % formic acid aque-
us solution was used with a flow rate of 1 mL/min. However, it
esulted in poor retention for both analytes on the trapping column
Fig. 1). Therefore, the effect of the flow rate of the diluting eluent on
etention was investigated in the range of 1–3 mL/min. Fig. 3 shows
hat, by increasing the flow rate up to 3 mL/min, trapping efficien-
ies were only slightly improved. These negligible changes can be
xplained by the pKa values of DMT  (8.68) [20] and AMT  (9.96) [21].
 comparison revealed that at low retention in the RP mode using
f 0.1 % formic acid aqueous diluter solution with a pH of 2.7, the
rotonated forms of DMT  and AMT  were the dominant species. It
eemed obvious that the retention of AMT  and DMT  on the trapping
olumn can be enhanced by suppressing the polar cationic forms
y increasing the pH of the diluter solvent. The increase of pH up to
0.2 in aqueous ammonia solution was an acceptable compromise
onsidering the sufficient trapping of the two analytes and the pH
tability of both the trapping and the Omega C18 columns. Fig. 3
emonstrates the dramatic improvement of trapping efficiency of
MT and AMT  by the increase of pH of the diluter solvent. For DMT,
igher enhancement was found, which could be explained by its
ower pKa value by ∼1.3 units compared with that of AMT.and  AMT  during trapping of the heart-cut 1D eluate in the range of 1–3 mL/min
(0.1 % FA), and 3 mL/min (ammonia solution at pH 10.2). The percentage increases
compared to consecutive experiments are indicated by curved arrows.
Fig. 1 (A) displays the schematic diagram of our 2D-LC-
HRMS/MS system in P̈osition 1′′ status, where the C̈18 Trapc̈olumn
was used to trap DMT  and AMT  from the dilute effluent of the HILIC
column. During the trapping period, the gradient program of HILIC
method was in isocratic section (Table 1). The system was kept
in trapping configuration from 1.8 min  to 3.49 min. At 3.50 min
the switching valves were turned into P̈osition 2′′ and thus C̈18
trapc̈olumn was  connected to the RP analytical column as shown
in Fig. 1 (B).  The particular design of the eluent gradient program
was applied to wash out trapped analytes from C̈18 trapc̈olumn
onto C18 analytical column, where the chromatographic separation
occurred followed by HRMS/MS detection of DMT  and AMT. Table 1
summarizes the final setup of events and gradient time programs
in both dimensions. To keep the short 10 min  2D run time, the HILIC
column was washed and equilibrated from 3.5 to 10 min, while the
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Main validation parameters of 2D-LC-HRMS/MS method.
Plasma Brain
Repeatability of retention time range (min) 4.99 ± 0.01 4.99 ± 0.01
LOD 0.108 ng/mL 0.212 ng/g
LOQ 0.328 ng/mL 0.642 ng/g
Accuracy Low (%) 111.7 111.6
Accuracy Mid  (%) 89.6 88.5
Accuracy High (%) 102.6 100.9
Precision Low (%CV) 2.8 2.7
Precision Mid  (%CV) 1.4 5.1
Precision High (%CV) 1.4 1.3
Carry over (%) 0.056 0.078
Stability (%) −0.452 −0.500ig. 4. Extracted ion chromatograms of quantifier ion transition of DMT and AMT  d
tandard solution.
rap and C18 columns were in the ranges of 8–10 min  and up to 3.5
in  in the next run using eluent and the flow rate gradient pro-
ram in both dimensions. The obtained 10 min  total run time was
aster than various published one dimensional LC–MS/MS methods
or DMT  analysis in brain and plasma [15–18]. The elution profiles
f DMT  and AMT  in the final 1D and 2D chromatograms of standard
olutions are shown in Fig. 4 (A, B).
.2. Determination of extraction recovery, matrix effect, process
fficiency and main validation parameters
Hence, the challenge of this work was to find a relatively sim-
le sample preparation procedure, which is suitable for enrichment
f DMT  from rat plasma and brain samples. In the literature, sev-
ral sample preparation methods related to DMT  are reported
10,15–18,22,23]. Unfortunately, in many cases the main param-
ters, such as extraction recovery (RE), matrix effect (ME), process
fficiency (PE), characteristics of the efficiency of a given method,
ere not presented. Labour-intensive and expensive solid-phase
xtraction procedures are widely employed nowadays for the
nrichment of DMT  from mammalian tissues [10,15,16]. The appli-
ation of 2D-LC has an ability to decrease the negative matrix effect
nder analysis thereby providing an opportunity to simplify the
ample preparation procedure. Therefore, the liquid–liquid extrac-
ion procedure seemed to be an obvious choice for the development
f a new method. Without detailing the process optimisation of the
ample preparation procedure, the use of ethyl acetate as organic
olvent and a basic pH in sample solution helped to enrich DMT
roperly in the case of plasma and brain samples (Fig. 5 (A, B)).
he relevant RE, ME  and PE of the new method were determined in
ccordance with the procedure of Matuszewski et al. and Cappiello
t al. [24,25]
Fig. 5 (A, B) illustrates the main indicators (RE, ME and PE) of
he new analytical method for DMT  and AMT  in rat plasma (20
g/mL) and brain (17.5 ng/mL). For DMT, the obtained 90 % of RE
f our new sample preparation procedure in plasma was better
ith approximately 20–30 % than data in early studies [17,18]. The
btained high mean values of RE with really good repeatability (∼Limit of detection (LOD), limit of quantification (LOQ) and percent coefficient of
variation (%CV).
10 % SEM) for DMT  and AMT  standard reveal that our new extrac-
tion methods are well-suited for both plasma and brain samples.
The presence of strong ionisation enhancement during HRMS/MS
detection resulted in a high positive ME  value of DMT  from plasma
(161 %) and brain (174 %). The obtained high ME  in plasma was
much favourable than reported by Meyers (46 %) in 2014 [17].
However, by investigating ME  of AMT, moderate ion suppression
occurred resulting in a value of 87 % in brain (Fig. 5 (B)). Overall, the
obtained favourable ME  values for both compounds from a complex
biological matrix clearly indicated the benefit of application of this
2D-LC-HRMS/MS method. In the case of DMT, the 145 % (plasma)
and 153 % (brain) of PE, as resultants of values of RE and PE, lend
evidence to the adequacy of the new method (Fig. 5 (A, B)).
For brain and plasma samples, the main validation parameters
of DMT  are summarized in Table 3. After full optimization of the 2D
method, good repeatability of the retention time of DMT  with in the
range of 4.98–5.00 min  was achieved. During method development,
the main issue was to keep the required volume of plasma as low
as possible in order to decrease the negative effect of blood collec-
tion during surgical procedures [26]. For DMT, our 2D-LC-HRMS/MS
method provided 0.108 ng/mL of LOD using 50 L of plasma, which
is significantly better than those reported in earlier studies, such as
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Fig. 5. Extraction recovery, matrix effect and process efficiencies for DMT  (plasma:
20  ng/mL, brain: 17.5 ng/mL) and AMT  (plasma: 20 ng/mL, brain: 17.5 ng/mL) stan-
dards from rat plasma (A) and rat brain homogenate (B). The extraction recovery and
matrix effect percentage were calculated as follows: Extraction recovery (%) = C/B
×  100, Matrix effect (%) = B/A × 100 and Process efficiency (%) = C/A × 100, where A
represents the average peak area of the standard solution, B represents the average
















the endogenous DMT  was  not detectable in the brain of control ani-tandard and C represents the average peak area of a plasma or brain pre-spiked at
he same concentration of the standard.
00 ng/mL using 500 L plasma [17] and 0.45 ng/mL from 200 L
lasma [18]. Interestingly, Oliveira et al. reported 0.1 ng/mL of LOD
or DMT  in plasma [16]. However, the solid phase extraction pro-
edure of their analytical method required 1000 L of plasma. In
rain sample the achieved LOD of DMT  in our case was also better
han that reported by Barker et al. (0.5 ng/g) [15].
The calibration curves (Figs. S13–S24) for DMT  were linear (R2
 99 %) in the range of 0.2–200 ng/mL plasma and 1.75–350 ng/g
rain. Accuracy of our new method in three different concentration
evels were determined within an acceptable interval of 12 % in
lasma and brain samples. The precisions were found to be ≤2.8 %
oefficient of variation (CV) in case of plasma and ≤5.1 % CV (brain).
he obtained carry over of DMT  was negligible (<0.08 %) in plasma
nd brain.utical and Biomedical Analysis 191 (2020) 113615
3.3. Quantification of DMT in rat plasma and brain
In the first dimension of our orthogonal 2D method, HILIC mode
was applied for the separation of DMT  and AMT from plasma
and brain matrix-derived endogenous components. In the method
development process, an important consideration was to cut the
peaks of interest from 1D to 2D in a narrow time window (1.8
min  for 3.5 min), thus to keep the amount of undesirable exo-
and endogenous matrix compounds in a low level in the second
dimension. It is worth to be noted that the trapping process at basic
pH also decreased the amount of compounds with acidic charac-
ter with a chromatographic behaviour similar to those of DMT  and
AMT  in HILIC condition. For these reasons, a relatively fast gradient
method was  applied in the second dimension. The obtained ME  val-
ues confirmed the validity of the steep RP gradient program applied.
Another advantage was that AMT  as internal standard allotted with
DMT  as targeted compound at same retention time, but not in dead
time, which is the chromatographic expectation of the standard
calibration method towards an internal standard (Figs. S1–S4).
The developed method was  applied to the quantification of DMT
in rat plasma and brain tissue. The main aims of the application
of this new 2D-LC-HRMS/MS method were to follow the plasma
DMT  level before ischemia onset, under ischemia, after hypoxia
and under reperfusion, and determination of DMT  concentration
in related brain tissue after reperfusion. Therefore, the plasma and
brain samples of preliminary experiments were used for optimi-
sation of the sample preparation procedure and determination of
the concentration range of external calibration using internal stan-
dards. A wide calibration concentration range was attempted for
quantification of endogenous and exogenous DMT  levels in a single
run. To our knowledge, there exists only a single report from 2005
in which endogenous DMT  was quantified in both rat brain and
plasma using isoctratic LC–MS/MS method [10]. Unfortunately, we
could not confirm the presence of endogenous DMT  in rat brain and
plasma. It is important to note, however, that our 2D-LC-HRMS/MS
method provided more reliable data due to 2D-LC separation and
accurate high resolution mass spectrometry detection with related
strict LC and HRMSMS confirmatory criteria: specific retention time
(4.99 min) with two  characteristic precursor–product ion transi-
tions using 50 ppm mass accuracy (quantifier ion at 58.0651 m/z
and qualifier ion at 144.0808 m/z) and the ratio of the peak area
of the quantifier ion and qualifier ion (2.1 ± 0.21) (Figs. S5–S12).
Despite the fact that the quantifier ion was  detected, but one the
above-mentioned other parameters was not completed, the con-
centration of DMT  was found to be lower than the limit of detection.
In the final method, the calibration curve was optimised to mea-
sure exogenous DMT  level, and DMT  showed a good linearity range
of 0.2–200 ng/mL plasma and 1.75–350 ng/g brain with R2 values
higher than 0.99 (Figs. S13, S14).
The level of DMT  in plasma samples of treated rats is illustrated
in Fig. 6 (A). All plasma samples collected before administration of
DMT  showed less than the detectable amounts of DMT. The high-
est concentration of DMT  in the range of 49.3–114.3 ng/mL was
observed in plasma for each animal before hypoxia. For animals 1,
3 and 4, the concentrations of DMT  decreased significantly after
hypoxia in plasma. After hypoxia to the end of the treatment, the
concentration of DMT  decreased to a mean value of 3.8 ng/mL, in
line with the termination of DMT  application.
Another question that remains to be answered is whether
DMT accumulates to a detectable concentration in the brain. Thus,
endogenous and exogenous DMT  were analysed in brain tissue in
both the control and treated animals. Similar to plasma samples,mals. However, after treatment, the concentration of DMT changed
in the range of 2–6.1 ng/g brain (Fig. 6 (B)).





















ig. 6. The obtained concentration of DMT  in plasma (A) and brain (B). Three
epeated measurements were used for statistical analysis (*p ≤ 0.05; ** p ≤ 0.01; ***
 ≤ 0.001).
The concentrations of exogenous DMT  measured are consid-
red to be underestimated of the actual concentrations, because
MT  must have been rapidly degraded during collecting biological
amples [27], in particular, when harvesting brain tissue.
. Conclusion
This paper describes the development and application of a fast
eart-cutting 2D-LC-HRMS/MS method and related liquid-liquid
xtraction procedure for the analysis of DMT. By connecting orthog-
nal HILIC and RP chromatography through the use of RP trap
olumn and high resolution MS/MS  detection, a sensitive and
elective analytical method was successfully utilised within total
un time of 10 min  for determination of the concentration of
MT  in rat plasma and brain of experimental model of cerebral
schemia/reperfusion using DMT  administration The developed
nd optimised plasma and brain matrix-related sample prepara-
ion protocols provided high extraction recoveries (∼90 %) and
igh positive matrix effect (plasma: +61 %, brain: ∼ +74 %) of
MT. During analysis, DMT  was identified and confirmed by its
pecific retention time in the second dimension, two  character-utical and Biomedical Analysis 191 (2020) 113615 9
istic precursor–product ion transitions and the ratio of quantifier
to qualifier mass transitions. External calibration using internal
standard was applied to obtain accurate concentrations of DMT
in plasma and brain samples. This heart-cutting 2D-LC-HRMS/MS
method with new sample preparation procedure gave an opportu-
nity to improve the LOD with the decrease of the required amount
of biological samples.
Concerning exogenous DMT, to the best of our knowledge, this is
the first attempt to confirm – with an analytical tool – the presence
of DMT  administered with therapeutical purpose in mammalian
tissues. In summary, our analytical approach is suitable to detect
and confirm the presence of DMT  administered to experimental
animals with therapeutic purpose. Further refinement of biologi-
cal sample harvesting will provide more accurate determination of
actual DMT  concentrations.
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